Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

728 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-05-08

Study Completion Date

2033-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Relugolix Pregnancy Registry is a prospective, observational cohort study designed to evaluate the association between relugolix-containing therapy exposure during pregnancy and subsequent maternal, fetal, and infant outcomes. Data will be collected from enrolled pregnant women and the healthcare providers (HCPs) involved in their care or the care of their infants, if applicable.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy

NCT06113237

Maternal Complications Pregnancy Complication Birth Outcomes, Adverse +1 more

RECRUITING

Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia

NCT01566630

Pre-eclampsia

TERMINATED PHASE2

Evolocumab Pregnancy Exposure Registry

NCT02957604

Hypercholesterolemia; ASCVD; Pregnancy

TERMINATED

COVID-19 International Drug Pregnancy Registry

NCT05013632

Covid19

RECRUITING

Study to Evaluate the Safety of Repatha® in Pregnancy

NCT02906124

Hypercholesterolaemia Pregnancy

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The outcomes of interest include major congenital malformation (MCM; primary outcome), minor congenital malformation, spontaneous abortion (SAB), stillbirth, elective termination, small for gestational age (SGA), preterm birth, postnatal growth deficiency, and infant developmental deficiency.

Pregnancy outcomes will be assessed throughout pregnancy, with data collection occurring at enrollment, the end of the second trimester, and pregnancy outcome. Infant outcomes will be assessed throughout the infant's first year of life, with active data collection by the registry occurring at 4 and 12 months after delivery. Enrolled pregnant women and the healthcare providers (HCPs) involved in their care or the care of their infants, if applicable, will serve as data reporters to the registry.

The registry is strictly observational; the schedule of office visits and all treatment regimens will be determined by HCPs. Only data that are documented in patients' medical records during the course of medical care will be collected. No additional laboratory tests or HCP assessments will be required as part of this registry.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy Related Pregnancy Complications Pregnancy, High Risk

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exposed Cohort

Pregnant women who are exposed to relugolix-containing therapy at any time during pregnancy

Relugolix-Containing Product

Intervention Type DRUG

Any relugolix-containing therapy

Unexposed Cohort

Pregnant women with conditions for which relugolix-containing therapy may be prescribed for indications that are approved or under phase 3 development and who are not exposed to relugolix-containing therapy at any time during pregnancy

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Relugolix-Containing Product

Any relugolix-containing therapy

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TAK-385 T-1331285 RVT-601 MVT-601 MVT-601A MYFEMBREE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Woman of any age
* Currently or recently pregnant
* Consent to participate
* Authorization for her HCP(s) to provide data to the registry

Cohort 1

* Exposure to at least one dose of relugolix-containing therapy at any time during pregnancy

Cohort 2

* Diagnosis of a condition for which relugolix-containing therapy may be prescribed and who are not exposed to relugolix containing therapy at any time during pregnancy

Exclusion Criteria

The following will be eligible for enrollment, included in supplementary analyses, but excluded from the analysis population:

* Occurrence of pregnancy outcome prior to first contact with the registry coordination center (retrospectively enrolled)
* Exposure to known teratogens and/or investigational medications during pregnancy
* Lost to follow-up

Minimum Eligible Age

0 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No